Kim TY, et al. - An ASBMR task force examined women, treated for either ≥5 years with oral alendronate in the Fracture Intervention Trial Long-term Extension (FLEX) or ≥3 years with intravenous zoledronic acid in the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial Extension I (HORIZON-PFT E1), with reassessment 2-3 years later, to compare the changes in bone mineral density (BMD) and procollagen type I N propeptide, procollagen type I N propeptide (PINP), after oral or intravenous bisphosphonate use. Three years after bisphosphonate discontinuation, a considerable proportion of former alendronate and zoledronic acid users had meaningful decreases in total hip BMD and PINP elevations. Alendronate might have a faster offset of drug impact than zoledronic acid despite a longer course of therapy.